I've been suffering from anxiety for a while now and thought I'd try this... I drink tea regularly and decided to put it in my zen tea. The peppermint flavor in it compliments really well and I've noticed a decline in my anxiety. Its honestly such a nice soothing relief. I would recommend this to anyone who suffers from anxiety and wants a natural remedy.
Cannabis is known to aid relaxation, which makes it a popular treatment for social anxiety – however due to the THC content in cannabis, it can actually trigger more intense feelings of paranoia and anxiety. CBD on the other hand, has the opposite effect, helping to calm down the nerves and keep you grounded. Anxiety disorders and other feelings of irrational fear can be overwhelming especially if you find yourself in unfamiliar environments, however CBD can be used effectively to generate calmness and peacefulness, and without the addictive component of anti-anxiety medication like Benzos or Xanax.
Imagine not being able to sleep and becoming chronically sleep deprived. Imagine not being able to find a comfortable position to sit, stand or sleep. Imagine your significant other or children wanting your attention and you not having the capacity to give any. Imagine not being able to have enjoyable sex with the one you love. Experiencing chronic pain continuously changes you. It will make you crazy. Depression and anxiety are commonplace among this patient population.
The degree to which cannabinoid analgesics will be adopted into adjunctive pain management practices currently remains to be determined. Data on Sativex use in Canada for the last reported 6-month period (January-July 2007) indicated that 81% of prescriptions issued for patients in that interval were refills (data on file, from Brogan Inc Rx Dynamics), thus indicating in some degree an acceptance of, and a desire to, continue such treatment. Given their multi-modality effects upon various nociceptive pathways, their adjunctive side benefits, the efficacy and safety profiles to date of specific preparations in advanced clinical trials, and the complementary mechanisms and advantages of their combination with opioid therapy, the future for cannabinoid therapeutics appears very bright, indeed.
It should be noted that recreational use of marijuana (high THC, low CBD cannabis) does result in dependence (but different from narcotics or alcohol, and not as debilitating). Chronic use of THC may be associated with atrophy in certain areas of the brain and reduction of certain cognitive functions (at this point, studies are not conclusive). Interestingly, studies have shown that taking CBD oil regularly can restore areas of the brain that have become atrophied in marijuana abusers.
Grant says this may lead to a “dampening” or mellowing of some neurochemical processes, including those linked to pain. “CBD may also react with other receptors, like those for serotonin, and it may have actions that reduce the inflammatory molecules produced whenever there is tissue damage or bacteria coming in,” he says. “But we really don’t know the mechanisms.”
The glutamatergic system is integral to development and maintenance of neuropathic pain, and is responsible for generating secondary and tertiary hyperalgesia in migraine and fibromyalgia via NMDA mechanisms (Nicolodi et al 1998). Thus, it is important to note that cannabinoids presynaptically inhibit glutamate release (Shen et al 1996), THC produces 30%–40% reduction in NMDA responses, and THC is a neuroprotective antioxidant (Hampson et al 1998). Additionally, cannabinoids reduce hyperalgesia via inhibition of calcitonin gene-related peptide (Richardson et al 1998a). As for Substance P mechanisms, cannabinoids block capsaicin-induced hyperalgesia (Li et al 1999), and THC will do so at sub-psychoactive doses in experimental animals (Ko and Woods 1999). Among the noteworthy interactions with opiates and the endorphin/enkephalin system, THC has been shown to stimulate beta-endorphin production (Manzanares et al 1998), may allow opiate sparing in clinical application (Cichewicz et al 1999), prevents development of tolerance to and withdrawal from opiates (Cichewicz and Welch 2003), and rekindles opiate analgesia after a prior dosage has worn off (Cichewicz and McCarthy 2003). These are all promising attributes for an adjunctive agent in treatment of clinical chronic pain states.